Connor, Clark & Lunn Investment Management (CC&L)
PRCT icon

Connor, Clark & Lunn Investment Management (CC&L)’s Procept Biorobotics PRCT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-49,126
Closed -$3.96M – 1564
2024
Q4 		$3.96M Buy
49,126
+32,015
+187% +$2.74M 0.02% 547
2024
Q3 		$1.37M Buy
+17,111
New +$1.22M 0.01% 781

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PRCT Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Procept Biorobotics (PRCT) in Q1 2025, closing a stake of 49,126 shares — an estimated $3.96M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PRCT in Q3 2024 and held it in 2 quarters. The position peaked at $3.96M in Q4 2024. 279 funds tracked by Wall St. Rank hold PRCT as of Q1 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Procept Biorobotics position as of Q1 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 49,126 Procept Biorobotics shares in Q1 2025, an estimated $3.96M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Procept Biorobotics in Q3 2024 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Procept Biorobotics position peaked at $3.96M in Q4 2024.
  • 279 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.